Article
Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study.
CNS oncology - 1 Sept 2020
Tejera Dalissa, Kushnirsky Marina, Gultekin Sakir H, Lu Min, Steelman Lori, de la Fuente Macarena I
Abstract excerpt
Glioblastoma is the most common and aggressive primary brain tumor. Despite standard multimodality therapy, median overall survival remains poor with a 5-year survival rate of approximately 5% in most studies (range 4.7-13.0%). Strong interest in targeting IDH mutations has led to a variety of studies in both hematologic malignancies and solid tumors and to the approval of IDH inhibitors such as ivosidenib, an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.